Back

Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure - pharmacotherapy 1 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Anthony Peters

Duke University Health System, Durham (United States of America)

7 More presentations in this session

Presentation thumbnail
COR-1167, a new long-acting CRF2 receptor agonist, decreases congestion by improving cardiorenal function in a sheep model of worsening heart failure (WHF)
Doctor P. Janiak (Paris, FR)
Abstract Slides Video
Presentation thumbnail
The impact of intrarenal venous doppler-guided diuretic management on hospital stay
Doctor M. Passos (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Mild-to-moderate chronic kidney disease predicts underutilisation of guideline-directed medical therapies in patients with acute heart failure
Associate Professor M. Polovina (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Response to up-titration of therapies in patients with new-onset heart failure with and without atrial fibrillation
Ms A. Zandijk (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Heart failure early post discharge appointment: a 2.5-year single-center experience
Doctor M. Passos (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure - pharmacotherapy 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources